Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final …
Y Kobayashi, K Tobinai, A Takeshita, K Naito… - International journal of …, 2009 - Springer
The primary objective of this study was to investigate the tolerability, efficacy and
pharmacokinetic profile of gemtuzumab ozogamicin (GO) in patients with relapsed and/or …
pharmacokinetic profile of gemtuzumab ozogamicin (GO) in patients with relapsed and/or …
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia
PF Bross, J Beitz, G Chen, XH Chen, E Duffy… - Clinical cancer …, 2001 - AACR
Abstract Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia,
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …
PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a …
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
R Stasi - Expert opinion on biological therapy, 2008 - Taylor & Francis
Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers, RA Larson, EA Stadtmauer… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: Three open-label, multicenter trials were conducted to evaluate the efficacy and
safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories …
safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories …
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
RA Larson, EL Sievers, EA Stadtmauer, B Löwenberg… - Cancer, 2005 - Wiley Online Library
BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab
ozogamicin (GO)(Mylotarg®), an antibody‐targeted chemotherapy for CD33‐positive acute …
ozogamicin (GO)(Mylotarg®), an antibody‐targeted chemotherapy for CD33‐positive acute …
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse
EL Sievers - Expert opinion on biological therapy, 2001 - Taylor & Francis
Gemtuzumab ozogamicin (CMA-676, Mylotarg®), an antibody-targeted chemotherapy
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …
Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
P Chevallier, B Mahe, R Garand, P Talmant… - International journal of …, 2008 - Springer
Gemtuzumab Ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with a
cytotoxic antitumor antibiotic, calicheamicin-g1. It was developed at the end of the nineties …
cytotoxic antitumor antibiotic, calicheamicin-g1. It was developed at the end of the nineties …
Acute and long-term toxicities associated with gemtuzumab ozogamicin (mylotarg®) therapy of acute myeloid leukemia
LH Leopold, MS Berger, J Feingoldr - Clinical Lymphoma, 2002 - Elsevier
Gemtuzumab ozogamicin (Mylotarg®) targets leukemia cells that express CD33 by means of
a humanized anti-CD33 monoclonal antibody conjugated to a modified antitumor antibiotic …
a humanized anti-CD33 monoclonal antibody conjugated to a modified antitumor antibiotic …
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
S Lapusan, MB Vidriales, X Thomas, S De Botton… - Investigational new …, 2012 - Springer
The efficacy of anti-CD33 immunoconjugates had been previously demonstrated for
gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by …
gemtuzumab-ozogamicin. AVE9633 is an anti-CD33-maytansine conjugate created by …
Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia
IA Voutsadakis - Anti-Cancer Drugs, 2002 - journals.lww.com
Abstract Gemtuzumab Ozogamicin (GO, CMA-676) is a monoclonal antibody against the
cellular surface antigen CD33 conjugated with the cytotoxic antibiotic calicheamicin. In the …
cellular surface antigen CD33 conjugated with the cytotoxic antibiotic calicheamicin. In the …